Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz4. fázis

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

A legfontosabb adatok

Ki végzi
BeiGene
Hol
Kína6 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Fázis
4. fázis
Résztvevők
16 fő vett részt
Kezdés
2025. okt. 17.
Várható befejezés
2028. okt. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Zanubrutinib
A regiszteradat frissítve
2026. augusztus 10.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Clinical and definitive histologic diagnosis of WM. Participant must be treatment-naive
  • Participant must meet at least 1 criterion for treatment according to consensus panel criteria from the Seventh International Workshop on Waldenström's macroglobulinemia (IWWM)
  • Participant must have measurable disease, as defined by serum immunoglobulin M (IgM) level > 0.5 g/dL
  • Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
  • Participants must have adequate organ function as indicated by the following laboratory values ≤ 7 days before the first dose of study treatment:; Participants must not have required blood transfusion or growth factor support ≤ 7 days before sample collection at screening for the following:; Absolute neutrophil count (ANC) ≥ 0.75 x 10\^9/L; Platelets ≥ 50 x 10\^9/L; Creatinine clearance of ≥ 30 ml/min as estimated by the Cockcroft-Gault formula; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN); Serum total bilirubin ≤ 2 x ULN (total bilirubin must be < 3 x ULN for participants with Gilbert syndrome)
  • Female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for at least 1 month after the last dose of zanubrutinib. They must also have a negative urine or serum pregnancy test result ≤ 7 days before the first dose of study treatment

Ki nem vehet részt

  • Central nervous system (CNS) involvement by WM. Patients with a history of CNS involvement must undergo magnetic resonance imaging (MRI) and cerebrospinal fluid cytology studies to document no evidence of CNS disease prior to study entry
  • Participants with any of the following cardiovascular risk factors:; Active cardiac ischemia (eg, cardiac chest pain) ≤ 28 days before first dose of study drug; Any history of acute myocardial infarction ≤ 6 months before the first dose of study drug; Any history of heart failure meeting New York Heart Association (NYHA) Classification III or IV (Appendix 7)≤ 6 months before the first dose of study drug; Any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before the first dose of study drug; Active, clinically significant second-degree atrioventricular block Mobitz II, or third degree atrioventricular block; Any history of cerebrovascular accident ≤ 6 months before the first dose of study drug; Uncontrolled hypertension that cannot be managed by standard antihypertension medications ≤ 28 days before the first dose of study drug; Any episode of syncope or seizure ≤ 28 days before first dose of study drug
  • Participants requiring ongoing therapy with strong or moderate cytochrome CYP3A inducers
  • Corticosteroids given with antineoplastic intent within 7 days, or chemotherapy, targeted therapy, or radiation therapy within 4 weeks, or antibody-based therapy within 4 weeks before the start of study drug
  • Major surgical procedure within 4 weeks before the start of study treatment (bone marrow aspirate and biopsy procedures are not considered major surgical procedures); Note: Other protocol defined criteria may apply
  • Evidence of disease transformation at the time of study entry
  • Evidence of disease transformation at the time of study entry
  • At the time of study entry, participants taking warfarin or other vitamin K antagonists

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to measure the efficacy and safety with zanubrutinib in adults with Treatment-Naive (TN) Waldenström Macroglobulinemia (WM). The main objective of this Phase 4 study is to further characterize the efficacy of zanubrutinib in Chinese participants with TN WM in order to fulfill the post-marketing requirements from the National Medical Products Administration (NMPA). Safety data will be collected and evaluated in this study as well.

A vizsgálat csoportja

  • ZanubrutinibA vizsgált kezelés

    Participants will receive 160 mg zanubrutinib orally twice a day until progressive disease, unacceptable toxicity or death, withdrawal of consent, loss to follow-up, or study termination by the sponsor for any reason.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 4, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Patients With Treatment-Naive Waldenström Macroglobulinemia
A regiszteradat frissítve
2026. augusztus 10.